Delcath Systems Inc Total Assets
Delcath Systems Inc total assets. Based on the latest financial reports, Delcath Systems Inc (DCTH) holds total assets worth $124.84 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Delcath Systems Inc for the company's overall valuation and market capitalisation.
Total Assets of Delcath Systems Inc (1999–2025)
Total assets of Delcath Systems Inc from 1999 to 2025. This chart illustrates how Delcath Systems Inc's total assets have evolved over time, based on quarterly financial data. See DCTH live share price for real-time trading data and today's change.
Delcath Systems Inc - Asset Composition Analysis
Delcath Systems Inc Total Assets Breakdown (December 2025)
Delcath Systems Inc total assets breakdown as of December 2025. Delcath Systems Inc's total assets of $124.84 Million consist of 96.7% current assets and 3.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.2% |
| Accounts Receivable | $11.74 Million | 9.5% |
| Inventory | $10.25 Million | 8.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Delcath Systems Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore DCTH current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Delcath Systems Inc's current assets represent 96.7% of total assets in 2025, an increase from 95.0% in 1999.
- Cash Position: Cash and equivalents constituted 35.2% of total assets in 2025, down from 93.3% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 9.5% of total assets.
Delcath Systems Inc Competitors by Total Assets
Key competitors of Delcath Systems Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Delcath Systems Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.24 | 15.95 | 3.99 |
| Quick Ratio | 10.33 | 14.61 | 3.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $109.57 Million | $79.06 Million | $17.16 Million |
Delcath Systems Inc - Advanced Valuation Insights
This section examines the relationship between Delcath Systems Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.57 |
| Latest Market Cap to Assets Ratio | 3.21 |
| Asset Growth Rate (YoY) | 61.4% |
| Total Assets | $123.63 Million |
| Market Capitalization | $396.31 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Delcath Systems Inc's assets at a significant premium (3.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Delcath Systems Inc's assets grew by 61.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Delcath Systems Inc (1999–2025)
The table below shows the annual total assets of Delcath Systems Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $123.63 Million | +61.42% |
| 2024-12-31 | $76.59 Million | +98.35% |
| 2023-12-31 | $38.61 Million | +116.17% |
| 2022-12-31 | $17.86 Million | -46.08% |
| 2021-12-31 | $33.12 Million | -4.36% |
| 2020-12-31 | $34.63 Million | +143.70% |
| 2019-12-31 | $14.21 Million | +107.66% |
| 2018-12-31 | $6.84 Million | -22.99% |
| 2017-12-31 | $8.89 Million | -74.78% |
| 2016-12-31 | $35.24 Million | +123.98% |
| 2015-12-31 | $15.73 Million | -33.79% |
| 2014-12-31 | $23.76 Million | -35.94% |
| 2013-12-31 | $37.10 Million | +21.73% |
| 2012-12-31 | $30.47 Million | -13.53% |
| 2011-12-31 | $35.24 Million | -30.32% |
| 2010-12-31 | $50.58 Million | +37.41% |
| 2009-12-31 | $36.81 Million | +224.04% |
| 2008-12-31 | $11.36 Million | -37.27% |
| 2007-12-31 | $18.11 Million | +106.60% |
| 2006-12-31 | $8.76 Million | -32.21% |
| 2005-12-31 | $12.93 Million | +75.85% |
| 2004-12-31 | $7.35 Million | +202.48% |
| 2003-12-31 | $2.43 Million | +34.14% |
| 2002-12-31 | $1.81 Million | -46.76% |
| 2001-12-31 | $3.40 Million | -42.65% |
| 2000-12-31 | $5.93 Million | +889.06% |
| 1999-12-31 | $600.00K | -- |
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more